Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.58 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | MC4R | P32245 | 1/20 | 0.58 |
| ▸ | FAP | Q12884 | 1/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.58 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.58 |
| ▸ | GHSR | Q92847 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3337964 | 0.91 | DPP4 (0.72) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL13324938 | 0.88 | DPP4 (0.62) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL13324367 | 0.88 | DPP4 (0.62) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL13324725 | 0.86 | DPP4 (0.62) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL13438222 | 0.83 | DPP4 (0.59) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL13324742 | 0.83 | DPP4 (0.69) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL2949897 | 0.83 | DPP4 (0.83) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL13324931 | 0.82 | DPP4 (0.62) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL13771186 | 0.82 | DPP4 (0.70) | DPP4CHRM1 | |
| SCHEMBL13324354 | 0.82 | DPP4 (0.65) | DPP4CHRM1POU2F2ADORA3POU2F1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-1562946-B1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2010-05-26 | — | — | EP | disclosed |
| US-7696212-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20090093457-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP7, DPP3 | DPP4 1/4885CHRM1 907/4885POU2F2 2239/4885 |
| US-20090093457-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP7, DPP3 | DPP4 1/4885CHRM1 907/4885POU2F2 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.